GlassScriptPhysician profile
Lori D Mcbride
NPI 1457450827
$1,929.38
in general payments reported to CMS, 2019-2025
20 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $443 · 2023: $326 · 2024: $292 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $370.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $362.06 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $296.18 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $137.96 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.71 | 2021-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $125.55 | 2021-2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $77.34 | 2021-2024 | |
| Amgen INC. | $76.51 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $56.03 | 2021-2023 | Farxiga |
| Scpharmaceuticals INC. | $42.98 | 2023 | |
| Irhythm Technologies, INC. | $41.55 | 2024 | Zio Monitor, Zio Xt Patch |
| Novo Nordisk INC | $34.67 | 2023-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $29.97 | 2025 | |
| Philips North America LLC | $27.57 | 2022-2023 | |
| Silk Road Medical, INC. | $23.16 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.76 | 2025 | Lux-Dx Insertable Cardiac Monitor |
| Astellas Pharma US INC | $21.18 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $19.84 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $13.63 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $13.57 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.